跳至主要内容
临床试验/NL-OMON54480
NL-OMON54480尚未招募不适用

Induction of neo*antigen specific cytotoxic T cells by autologous tumor lysate-loaded specialized cross*presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study - NEOadjuvant Dendritic cell vaccination for Ovarian Cancer (NEODOC)

Radboud Universitair Medisch Centrum0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Age over 18 years old
  • Histologically confirmed primary epithelial ovarian cancer
  • Not amenable by primary debulking surgery and in need of neoadjuvant
  • chemotherapy and interval debulking
  • High-grade serous histology
  • FIGO stage IIIb, IIIc, IVa or IVb if only lymph nodes <= 1cm above the
  • diaphragm or in the groins
  • Extensive abdominal spread of tumor
  • WHO/ECOG performance status 0-1

排除标准

  • Recurrent ovarian cancer
  • History of any second malignancy, with the exception of adequately treated
  • basal cell carcinoma, cervical cancer > 5 years ago or early stage breast
  • cancer >10 years ago.
  • Any serious clinical condition that may interfere with the safe
  • administration of DC vaccinations or renders patient ineligible for combined
  • carboplatin-paclitaxel chemotherapies
  • Active infection of Hepatitis B, C, HIV and syphilis or any other serious
  • active infection
  • Known allergy to shell fish
  • Auto immune disease (exception: vitiligo is permitted)
  • Chronic treatment with systemic immunosuppressive drugs (i.e. more than 10 mg
  • prednisolone equivalent)

研究者

相似试验